Clinical trialEPhase 1Withdrawn
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer: Establishing the Radiomic/Pathologic Foundation of Heterogeneity
- Outcome
- Stopped earlyLack of funding (Business decision)
- Phase
- EPhase 1
- Status
- Withdrawn
- Study type
- Interventional
- Start
- 1 April 2021
- Expected end
- 1 April 2023
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Radiosensitivity Index and Degree of Pimonidazole Staining
- Sponsor
- Other
- Results posted
- No
- Last update
- 8 February 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
At present there is no validated prognostic tool for patients with resectable pancreatic cancer (RPC) to determine how best to tailor individual therapy. This study is to see if tumor features in blood and imaging prior to surgery correspond with tumor heterogeneity in the specimen after surgery.
Detailed description public domain (ClinicalTrials.gov)
This study is to prospectively determine whether there is a predictive relationship in RPC between pre-operative radiomic imaging features and pathologic tumor heterogeneity, delineated by gene-expression-based RSI and histologic measures of hypoxia measured by Glut-1 and CA-IX as well as the degree of pimonidazole staining.